Dr. Satyanarayana Chava, founder and chief executive officer of Laurus Labs said the company is on path of diversification and strengthenin...

The company had reported a net profit of Rs 202 crore during the same period of the previous year. On a quarter-on-quarter (QoQ) basis , th...

The company attributed this to the change in the effective tax rate for Q1FY23 on account of a drop in SEZ profits exemption u/s 10AA to 50...

“We want to bring the drugs which are not available in India. The biggest factor is affordability. If you bring a medicine which is not aff...

It supplies active pharmaceutical ingredients (APIs) to nine out of the 10 largest generic pharma companies and has leadership positions in...

The earnings before interest, tax, depreciation and amortization (EBITDA) decreased 17% YoY to Rs 290 crore. The EBITDA margins dropped by ...

"We are happy to sign an agreement to manufacture the oral COVID-19 antirviral medication, which is an urgent need of the hour, this is one...

The pharmaceutical sector is the top performer in India’s $2.1 trillion equity market this year after the coronavirus pandemic turned globa...

India’s drug companies that come under essential services are handing out incentives and assurance of a sterile work environment to workers...

Buy Laurus Labs Ltd. at a price sequential targets Rs 590- 633 .

For the quarter ended September 2017, the company posted a 4.3% growth in its revenues to Rs 538.6 crore as against Rs 516.5 crore in the c...

Once the formulation business starts giving revenues, our gross margin in that business is straight away over PPT, says Satyanarayana Chava...

There are many facilities which have been inaugurated but are not giving any revenue. Once they start giving revenue, the company will have...

The connect between ISB and its alumni community is getting stronger every year with more alumni coming back to School to contribute in the...

While core promoters of Laurus led by Dr Chava Satyanarayana own majority stake of over 51% in the company, PE investors and global pharmac...

PE giant Carlyle Group and Advent International are in discussions for a $150-million (Rs 900-crore) investment deal in Laurus Labs.

S3V Vascular Technologies floated by four graduates of the ISB said it would set up a Rs 140 crore facility to develop products in Interven...